Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 12/20 | 0.54 |
| ▸ | CCR3 | P51677 | 12/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648874 | 1.00 | HRH1 (0.54) | HRH1CCR3KCNH2LMNAPOLB | |
| SCHEMBL3286028 | 0.83 | HRH1 (0.46) | HRH1CCR3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL3286021 | 0.83 | HRH1 (0.46) | HRH1CCR3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL3283140 | 0.83 | HRH1 (0.50) | HRH1CCR3KCNH2 | |
| SCHEMBL3282963 | 0.83 | HRH1 (0.48) | HRH1CCR3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL3282974 | 0.83 | HRH1 (0.48) | HRH1CCR3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL3283132 | 0.83 | HRH1 (0.50) | HRH1CCR3KCNH2 | |
| SCHEMBL1929589 | 0.81 | HRH1 (0.50) | HRH1CCR3KCNH2DRD2DRD4 | |
| SCHEMBL1929113 | 0.81 | CCR3 (0.54) | HRH1CCR3KCNH2DRD2DRD4 | |
| SCHEMBL5986597 | 0.81 | CCR3 (0.54) | HRH1CCR3KCNH2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956070-B2 | Piperidines as chemokine modulators (CCR) | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-1938274-A | Novel piperidines as chemokine modulators (CCR) | ASTRAZENECA AB (SE) | 2007-03-28 | — | — | CN | disclosed |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | HRH1 33/4885CCR3 2/4885KCNH2 862/4885 |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | CCR3, CCR1, CCR4 | HRH1 81/4885CCR3 1/4885KCNH2 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.